MedTrace Logo

"Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02491229 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-01-14

No results posted yet for this study

Summary

The purpose of this study is to investigate whether a weight reduction with "Hepafast" in combination with raw food and vegetables for two weeks followed by a meal substitution with "Hepafast" and a calorie restriction in accordance with the Low Glycemic and Insulinemic Diet (LOGI) for 10 weeks is superior regarding improvement of non-alcoholic Fatty Liver Disease (NAFLD) compared to a conventional weight reduction in accordance with the LOGI diet without use of "Hepafast" for 12 weeks.

Conditions

  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Obesity

Interventions

OTHER

Hepafast

Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet

OTHER

LOGI diet

For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).

Sponsors & Collaborators

  • Bodymed AG

    collaborator UNKNOWN

  • University of Hohenheim

    lead OTHER

Principal Investigators

  • Stephan C. Bischoff · University of Hohenheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-05-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491229 on ClinicalTrials.gov